New drug showdown: can this treatment shrink tumors before surgeons operate?
NCT ID NCT07398937
Summary
This study compares two immunotherapy drugs (serplulimab and nivolumab) when given with chemotherapy before surgery for stage II-IIIa squamous non-small cell lung cancer. Researchers want to see which combination better shrinks tumors and improves surgical outcomes for 116 eligible patients. The main goal is to measure how many patients have no detectable cancer left after this pre-surgery treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE STAGE II-IIIA SQUAMOUS NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.